Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Using molecular techniques to define risk in patients with myeloma

Ruben Niesvizky • 25 Oct 2021
LLM 2021
Multiple Myeloma Rare Diseases Smoldering Myeloma

Ruben Niesvizky, MD, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, gives an overview of a talk on using molecular techniques such as sequencing to define risk in patients with smoldering disease and extramedullary complications. These techniques will also help to better characterize these malignancies. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

More from Ruben Niesvizky

2:51
Key myeloma discussion topics at LLM 2021
Ruben Niesvizky • 25 Oct 2021
1:25
Moving CAR T-cell therapy and bispecific antibodies in the consolidation setting
Ruben Niesvizky • 25 Oct 2021
1:41
Innovative treatment strategies for multiple myeloma
Ruben Niesvizky • 25 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals